Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Lilly Files Tirzepatide for Obesity in Japan, Ties Up with Mitsubishi
Eli Lilly said on May 8 that it has filed for Japanese regulatory approval of its GIP/GLP-1 receptor agonist tirzepatide for the treatment of obesity. In Japan, the drug is already available for type 2 diabetes under the brand name…
To read the full story
Related Article
- Qalsody, Zepbound, Zeposia Inch Closer to Japan Approval with Panel OK
December 3, 2024
- Qalsody, Zepbound, Zeposia Up for Advisory Panel Review on Dec. 2
November 19, 2024
BUSINESS
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Teijin Seeks Japan Nod for Ascendis’s GHD Drug
February 13, 2026
- Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026
- Takeda’s Narcolepsy Drug Accepted for US FDA Review
February 12, 2026
- FDA Rejects Regenxbio/Nippon Shinyaku’s MPS II Gene Therapy
February 12, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…